Lung Cancer: Molecular Pathways, Current Therapies and New Targeted Treatments
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 20 June 2024 | Viewed by 1425
Special Issue Editors
Interests: cancer; development of chemical compounds; lung cancer; autophagy; immunotherapy
Special Issue Information
Dear Colleagues,
According to the WHO, lung cancer constitutes the most lethal type of tumor and accounts for a huge number of deaths worldwide. In 2020, lung cancer caused near to 2 million deaths and 2.2 million new cases. The most common types of lung cancer are small-cell lung cancer (SCLC) and the non-small-cell lung cancer (NSCLC). Many scientific groups are working on lung cancer, producing deeper knowledge about its genetic background and risk factors. Smoking and air pollution have been recognized as two factors heavily augmenting the possibility of lung cancer development. Similarly to several other types of cancer, the traditional approaches of surgery, radiotherapy, and chemotherapy serve as treatment options for lung cancer. However, over the last decade, immunotherapy and target-specific drugs (e.g., Erlotinib, Gelfitinib, and Crizotinib) have been introduced to clinical practice. Nowadays, it has been proven that the disruption of cellular processes in cancer cells such as glucose metabolism, autophagy, apoptosis, and others can have a big impact on the efficacy of the treatment. Therefore, understanding the molecular mechanisms behind those disruptions could have a great impact on clinical practice by improving our current therapeutic options or by helping the development of new therapeutic approaches. The goal of this Special Issue is to highlight the new scientific achievements related to the molecular pathways that can serve as targets for new treatments or as targets enhancing the efficacy of current treatments.
Dr. Achilleas Mitrakas
Dr. Christos Kakouratos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- current therapies
- cancer cell metabolism
- autophagy
- NSCLC
- immunotherapy
- targeted treatments
